. 2014 Jul 30;9(7):e103593. doi: 10.1371/journal.pone.0103593

Table 5. Characteristics of previous studies.

Types of cancer	Study authors	Genes assessed	No. of SNPs assessed	No. of patients	No. of events	Follow-up period, yrs	Types of outcome^j	Adjusted covariates^k	Ref
Breast	Yang et al.	TLR4	4	604	-	4.9	OS	-	[11]
	You et al.	IL-21	4	891	121	5.0	OS	age, age at menarche (years), menstrual status, BMI, pathological type, stage, ER status, PR status, family history of any cancer	[12]
	Hu et al.	IL-2	2	638	-	5.0	OS	-	[13]
	DeMichele et al.	IL-6	4	346	-	11.2	DFS	age at diagnosis, race, CYP3A4, GSTM1	[14]
	Bewick et al.	ERCC1 and ERCC2	3	95	91	0.9 (PFS) 1.9 (BCSS)	PFS, BCSS	age	[53]
Colorectal	Lu et al.	REG4, BML, and CD209	15	414	203	4.7	OS	age at diagnosis, gender, TNM stage.	[54]
	Castro et al.	13 immune genes	19	582	150	13.0	OS	age at diagnosis, T, N stage.	[55]
	Slattery et al.	11 immune genes	50	1555^a	309	>5.0	OS	age, study center, ethnic group/ethnicity, sex, TNM stage, tumor molecular phenotype	[56]
				754^b	171	>5.0	OS
	Bondurant et al.	13 immune genes	59	1956^a	309	>5.0	OS	age, study center, ethnic group/ethnicity, sex, AJCC stage and tumor molecular phenotype	[57]
				954^b	171	>5.0	OS
Non-small cell lung	Bi et al.	Cox-2	5	136	-	5.0	OS	age, sex, smoking status, KPS, weight loss, histology, clinical stages, chemotherapy, radiation dosage	[58]
	Dai et al.	52 immune genes	178	568	311	6.0	OS	smoking status, histology, stage, surgical operation, chemotherapy, or radiotherapy status	[59]
	Sung et al.	FasL	1	385	124	2.6ⁱ	OS, RFS	age, gender, smoking, tumor type, stage	[60]
	Yuan et al.	TGF-β1	3	205	-	1.4ⁱ	OS, DMFS	age, sex, race, KPS, smoking status, tumor histology, gross tumor volume, disease stage, receipt of chemotherapy or concurrent radiochemotherapy, number of cycles of chemotherapy, and radiation dose received	[61]
	Xue et al.	TGF-β1	2	109	85	1.2ⁱ	OS	age, gender, smoking status, histology, stage, radiation technique, radiation dose, and chemotherapy	[62]
	Schabath et al.	53 inflammation-related genes	326	651	-	2.1ⁱ	OS	age, gender, race, smoking status, stage, histology and first-course treatment.	[63]
	Guan et al.	TNF-α and TNFRSF1B	5	225	155	1.9	OS	age, gender, ethnicity, smoking status, tumor histology, KPS, tumor stage, node status, application of chemotherapy and radiotherapy dose	[64]
	Pine et al.	MBL2	5	558 (white population)	405	3.8	OS	sex, stage (III–IV versus I-II), age at diagnosis, current smoking status, and pack-years of smoking	[65]
Bladder	Guirado et al.	C13ORF31, NOD2, TLR10, and RIPK2	5	349	66	3.9ⁱ	OS	-	[66]
Renal cell carcinoma	Schutz et al.	70 immune genes	290	403^c	184	5.3	RFS	ECOG performance status, clinical stage, tumour size, tumour Fuhrman grade, histology (clear cell vs non clear cell)	[67]
				151^c	44	8.8	RFS
Lymphoma	Aschebro-okkilfoy et al.	40 immune genes	82	496	211	12.0	OS	age, education, stage, B-symptom, initial treatment.	[68]
	Charbonneau et al.	30 immune genes	167	107^d	60	8.3	EFS	clinical risk score, which accounts for the effects of treatment type and FLIPI (FL) or IPI (DLBCL)	[69]
				82^e	39	8.3	EFS
	Habermann et al.	44 immune genes	73	365	96	4.8	OS	age and clinical and demographic factors.	[70]
	Cerhan et al.	44 immune genes	73	278	59	4.8	OS	age, clinical, demographic factors	[42]
Melanoma	Lenci et al.	15 type IFN genes	44	625	174	-	OS, DFS	gender, age and Breslow thickness	[71]
Ovarian	Goode et al.	54 immune genes	1536	3665	1529	5.4	OS	study site, tumor stage, race, tumorgrade	[72]
Pancreatic	Reid-Lombardo et al.	102 inflammatory genes	1536	400^f	318	2.0ⁱ	OS	age, sex, body mass index class, stage, margin status (R0, R1, R2), grade, tumor size, and lymph node status	[73]
				443^g	420	0.8ⁱ	OS
				465^h	454	0.6ⁱ	OS
Osteosarcoma	Biason et al.	XPD, XPG, and XPA	5	130	57	3.0	EFS	covariate which were significant in the univariate analysis	[74]
Esophageal	Lee et al.	ERCC2 and ERCC4	2	400	310	-	OS, PFS	T stage, N stage, Cell type, esophagectomy, CCRT	[75]
Head and neck	Lundberg et al.	TGF-β1	1	34	14	4.0	OS, DFS	age, sex, cisplatin dose (mg/m2), RT dose (Gy) and treatment modality	[76]
Myeloma	Vangsted et al.	IL-1β, IL-6, IL-10, PPARγ2, and COX-2	6	348	68	-	OS	β2-microglobulin, creatinine and Durie–Salmon stage	[77]

Colon cancer patients, ^bRectal cancer patients, ^c403 cases are discovery cohort and 151 cases are validation cohort, each cohort selected from different center, ^dFollicular lymphoma patients, ^eDiffuse large B-cell lymphoma patients, ^fPatients who had undergone pancreatic resection operation, ^gPatients whose cancer locally advanced, ^hPatients whose cancer had metastasized, ⁱMedian survival time, ^jOS, overall survival; DFS, disease free survival; RFS, relapse free survival; EFS, event free survival; DMFS, distant metastasis-free survival; BCSS, breast cancer specific survival, ^kAJCC, american joint committee on cancer; KPS, karnofski performance status; ECOG, eastern cooperative oncology group; CCRT, concurrent neoadjuvant chemoradiotherapy; FIGO, international federation of gynecology and obstetric.